Article

Interstitial lung diseases

Department of Veterinary Medicine and Surgery, University of Missouri-Columbia College of Veterinary Medicine, Columbia, MO 65211, USA.
Veterinary Clinics of North America Small Animal Practice (Impact Factor: 1.04). 10/2007; 37(5):937-47, vi-vii. DOI: 10.1016/j.cvsm.2007.05.008
Source: PubMed

ABSTRACT Several noninfectious nonneoplastic interstitial lung diseases (ILDs) have been recognized in dogs and cats. Overall, these ILDs are poorly characterized in dogs and cats, although awareness of the conditions based on descriptions of clinical case series may be increasing. Lung biopsy remains crucial to the diagnosis, characterization, and classification of ILDs. Histopathologic findings can help to guide clinicians in selecting appropriate therapy and providing an accurate prognosis to pet owners. Only with definitive recognition of these pulmonary conditions can our knowledge of the clinical course and response to therapy be improved.

Download full-text

Full-text

Available from: Leah Cohn, Apr 22, 2014
0 Followers
 · 
288 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To describe the clinical profile of interstitial lung disease in infancy. A retrospective analysis of cases diagnosed to have ILD was carried out in Kanchi Kamakoti CHILDS Trust hospital over a period of 2 yr. Infants aged 1 month to 1 yr of age were included if they had (1) respiratory symptoms (Cough, tachypnea or crepitations) for at least 1 month (2) diffuse infiltrates on chest radiography (3) Hypoxemia as defined by oxygen saturation less than 90% by pulse oximetry and (4) High Resolution Computed Tomography (HRCT) of the chest revealing findings of interstitial infiltrates or ground glass pattern. Their case records were analyzed for clinical data, treatment and follow up details. Of the 9 children, who were diagnosed to have ILD, 5 were boys and 4 were girls. The male: female ratio was 1.25: 1. The median age of onset of symptoms was 5 month. The common clinical features observed were tachypnea associated with chest indrawing (100%), cough (100%), hypoxia (100%), failure to thrive and fever (55%) each. The following radiographic patterns were observed in the chest skiagrams: reticulo-nodular pattern in 6(67%) and ground glass pattern in 3(33%). HRCT showed interstitial infiltrates in 6 (67%) and ground glass pattern in 3(33%). Evidence for cyto megalo virus (CMV) infection was detected in 5(56%), Adenovirus in 1 (11%) and Pneumocystis carinii (PCP) in 1(11%) infant. Open lung biopsy was performed in 2 infants, which detected CMV in 1 and PCP in the other. All children received oxygen therapy and systemic corticosteroids (oral/IV) in addition to specific therapy for infection and 3 of these infants succumbed to respiratory failure. CMV Infection was the commonest cause of ILD in infancy in our study. However, the consequences on long term follow up in these infants need to be ascertained.
    The Indian Journal of Pediatrics 08/2007; 74(7):637-9. DOI:10.1007/s12098-007-0113-z
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infiltration of T lymphocytes in the lungs is common in patients with and in animal models of pulmonary fibrosis. The role of these cells in regulating the accumulation of extracellular matrix, particularly collagen, is not understood completely. Research literature provides evidence for a profibrotic, an antifibrotic, or no significant role of T lymphocytes in pulmonary fibrosis. This review offers a discussion of such evidence with the focus on phenotypes of pulmonary T lymphocytes and related profibrotic and antifibrotic mechanisms. It appears unlikely that T lymphocytic infiltration per se is the central driving force in most cases of pulmonary fibrosis. Instead, evidence suggests that T lymphocytes may modulate the inflammatory and healing responses in the lungs in a profibrotic or antifibrotic manner, depending on their phenotype. Phenotypic reshaping, rather than elimination of the infiltrating pulmonary T lymphocytes, may be a promising approach to improving outcomes in patients with pulmonary fibrosis.
    Journal of Leukocyte Biology 03/2008; 83(2):237-44. DOI:10.1189/jlb.0707504